MedTrace Logo

A Study of CST-2032 in Subjects With Cognitive Impairment

NCT05033912 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2021-10-28

No results posted yet for this study

Summary

This study will evaluate the effects of CST-2032 when administered with pre-administered CST-107 on safety, tolerability, cognition, cerebral perfusion, and cerebral metabolism in patients with cognitive impairment.

Conditions

  • Mild Cognitive Impairment (MCI)
  • Parkinson Disease (PD)

Interventions

DRUG

CST-2032, matching placebo for CST-2032, CST-107

CST-2032 and matching placebo oral liquid; CST-107 white capsules

Sponsors & Collaborators

  • CuraSen Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Chief Medical Officer · CuraSen Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-31
Primary Completion
2022-03-31
Completion
2022-05-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05033912 on ClinicalTrials.gov